



Application of:

Rittershaus and Thomas

Serial No.:

09/943,334

Filed:

August 30, 2001

Entitled:

MODULATION OF CHOLESTERYL

ESTER TRANSFER PROTEIN (CETP)

ACTIVITY

Attorney Docket No.: TCS-411.1P US-1

RECEIVED

ART UNIT: 1644

EXAMINER: M. Belyavskyi

FFB 1 0 2003

Director of the U.S. Patent & Trademark Office Washington, D.C. 20231

TECH CENTER 1600/2900

AMENDMENT AND RESPONSE UNDER 37 CFR § 1.111

Sir:

Applicants submit this response to the Office Action (paper no. 6), mailed July 30, 2002, in the above-identified divisional application.

A Petition for a three-month extension of time in which to respond to the Office Action along with the appropriate fee under 37 C.F.R. § 1.17(a)(3) accompany this response. The Commissioner is hereby authorized to charge payment of any additional fees required in connection with this paper to Deposit Account No. 50-0268.

A terminal disclaimer under 37 C.F.R. § 1.321(c) with respect to the commonly assigned, copending U.S. application Ser. No. 08/432,483, now U.S. Patent 6,410,022, to which this application claims benefit under 35 U.S.C. §§ 120 and 121, and the appropriate fee under 37 C.F.R. § 1.20(d), also accompanies this response. The terminal disclaimer is filed to obviate an obviousness-type double patenting rejection set forth in the Office Action (page 13).

Please amend the above-identified application as follows:

02/07/2003 BSAYASI1 00000099 09943334

01 FC:2253

465.00 BP